Vinpocetine Attenuates Hepatic Steatosis by Modulating Key Lipogenic and Lipid Transport Genes (PPAR‐ γ, SREBP, and FAT/CD36) in Experimental Non‐Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a common metabolic disorder characterized by excessive lipid accumulation in hepatocytes and is strongly associated with obesity, insulin resistance, and dyslipidaemia. Targeting key regulators of hepatic lipid metabolism represents an important therapeutic strategy. Vinpocetine, a phosphodiesterase-1 inhibitor, exhibits metabolic and anti-inflammatory properties, but its role in hepatic lipid homeostasis remains insufficiently defined. To evaluate the effect of vinpocetine on hepatic steatosis and its regulatory impact on key lipid-metabolism genes, including peroxisome proliferator-activated receptor-α (PPAR-α), PPAR-γ, sterol regulatory element-binding protein-1c (SREBP-1c), and fatty acid translocase/cluster of differentiation 36 (FAT/CD36), in an experimental NAFLD model. NAFLD was induced in rats using a high-fat diet. Animals received vinpocetine (10 mg/kg, i.p.) daily for 5 weeks. Hepatic lipid accumulation was assessed histologically and biochemically, while gene expression of PPAR-α, PPAR-γ, SREBP-1c, and FAT/CD36 was analyzed using RT-PCR. Vinpocetine significantly reduced hepatic lipid accumulation compared with untreated NAFLD controls. It upregulated PPAR-α expression while downregulating PPAR-γ, SREBP-1c, and FAT/CD36, indicating enhanced fatty-acid oxidation and reduced lipogenesis and lipid influx. Treatment also improved lipid profile parameters (reduced TC, TG, LDL, and restored HDL), lowered liver enzyme levels, increased antioxidant activity (elevated glutathione), and reduced oxidative and nitrosative stress (decreased malondialdehyde and nitric oxide), accompanied by improved liver histology. Vinpocetine attenuates hepatic steatosis in NAFLD by modulating genes involved in lipid metabolism, suggesting potential therapeutic value. Further studies are required to confirm these findings and clarify mechanisms.

Authors

Institutions

Publication Details

Journal
Journal of Biochemical and Molecular Toxicology
Published
2026-06-29
DOI
https://doi.org/10.1002/jbt.71005
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Vinpocetine Attenuates Hepatic Steatosis by Modulating Key Lipogenic and Lipid Transport Genes (PPAR‐ γ, SREBP, and FAT/CD36) in Experimental Non‐Alcoholic Fatty Liver Disease

Bashir Alsiddig Yousef, Ekram Nemr Abd Al Haleem
Journal of Biochemical and Molecular Toxicology
Liver Disease Diagnosis and Treatment
article

Vinpocetine Attenuates Hepatic Steatosis by Modulating Key Lipogenic and Lipid Transport Genes (PPAR‐ γ, SREBP, and FAT/CD36) in Experimental Non‐Alcoholic Fatty Liver Disease

Bashir Alsiddig Yousef, Ekram Nemr Abd Al Haleem
article en

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a common metabolic disorder characterized by excessive lipid accumulation in hepatocytes and is strongly associated with obesity, insulin resistance, and dyslipidaemia. Targeting key regulators of hepatic lipid metabolism represents an important therapeutic strategy. Vinpocetine, a phosphodiesterase-1 inhibitor, exhibits metabolic and anti-inflammatory properties, but its role in hepatic lipid homeostasis remains insufficiently defined. To evaluate the effect of vinpocetine on hepatic steatosis and its regulatory impact on key lipid-metabolism genes, including peroxisome proliferator-activated receptor-α (PPAR-α), PPAR-γ, sterol regulatory element-binding protein-1c (SREBP-1c), and fatty acid translocase/cluster of differentiation 36 (FAT/CD36), in an experimental NAFLD model. NAFLD was induced in rats using a high-fat diet. Animals received vinpocetine (10 mg/kg, i.p.) daily for 5 weeks. Hepatic lipid accumulation was assessed histologically and biochemically, while gene expression of PPAR-α, PPAR-γ, SREBP-1c, and FAT/CD36 was analyzed using RT-PCR. Vinpocetine significantly reduced hepatic lipid accumulation compared with untreated NAFLD controls. It upregulated PPAR-α expression while downregulating PPAR-γ, SREBP-1c, and FAT/CD36, indicating enhanced fatty-acid oxidation and reduced lipogenesis and lipid influx. Treatment also improved lipid profile parameters (reduced TC, TG, LDL, and restored HDL), lowered liver enzyme levels, increased antioxidant activity (elevated glutathione), and reduced oxidative and nitrosative stress (decreased malondialdehyde and nitric oxide), accompanied by improved liver histology. Vinpocetine attenuates hepatic steatosis in NAFLD by modulating genes involved in lipid metabolism, suggesting potential therapeutic value. Further studies are required to confirm these findings and clarify mechanisms.

Journal of Biochemical and Molecular ToxicologyVol. 40(7)
University of Khartoum (SD), Al-Azhar University (EG), Ibn Sina National College for Medical Studies (SA)
Good health and well-being
Openalex Percentile: Top 7%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.